Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow one month and they have a product that could be approved next month. What laughs these guys are. Just like Celularity and Meso. We have been trying since 2001 to find direction and we are still waiting for ARS trial to begin. One day it will start. Not until the employee lottery is played though. I know your purpose here is to antagonize. But at least come up with something better than that.
Hopefully one day the last laugh will be on the firm. The one who brings out the big gun every once in a while like they did today. Brought them out the day of Meso talk, but went back into silence as to ignore the relevant questions. They are incapable of answering any of those hard questions I posed to them.
Want to hear a real stunner in comparing Meso to us. As of June 30th, 2017, they had 75 employees globally. What do we have 180? Look at all they have accomplished, with a substantially lower amount of employees.
Go take a look at their incentive program. Short term, long term goals. Options are used as incentives. Encourage your employees to achieve, which they obviously have.
And yes EichKing, looks like the Pluristem lottery coming soon will all be free shares. Apparently that is what it's been fro the last 3 years. Found this quote from Pluristem's 10-k.
"During fiscal years 2017, 2016 and 2015, there were no options granted to employees or directors."
This just gets worse the more you dig. No wonder there were some funky titles from that link I posted a little while back. 2 ceo's. A freaking embarrassment is what that is.
6 million shares locked and loaded to be given away in a few months. All awarded based on the judgement of some of our board members. Sickening is an understatement.
It truly is. That one was buried in an article from the 10K. Wonder why they put it there. The whole lot of them only care in the enrichment of themselves. No wonder none of them ever resign. Gravy train turning flops into wealthy individuals. Sickening in every sense of the word.
Don't forget this EichKing. It's never ending how happy they are to be a part of Pluristem. No wonder they made that video.
Our board is also entitled to 2.5% cash grab from non dilutive funding. 5% goes right out the door to the twins and directors when we get non dilutive funding. Hopefully it's not 2.5% each, since the wording is vague. Wouldn't surprise me in the least if it was each. What a sweet gig they have don't you think. I guess it's all based on their vast experience. It is, as you know, biotech!!!
https://www.sec.gov/Archives/edgar/data/1158780/000117891311002580/exhibit_10-8.htm
"The directors are also entitled to two and a half percent (2.5%) from amounts received by us from non diluting funding and strategic deals."
It's funny how the majority of our board, have anywhere from $500,000 to $750,000 is stock. Not options, stock. Sit on our board and you will be rewarded handsomely. Those what, 12 meetings a year are pretty tough after all. I'm not even sure if it's that, but probably pretty close. Tough job doing nothing on behalf of shareholder value isn't it. Not quite sure they understand who they are to represent. But like always, it's biotech!!!
It couldn't be could it EichKing? LMBO. Good value at this price is pretty funny to say the least. What will be said when we hit the $1.20's as we have briefly touched, and likely to return. Don't know what that makes the plus $2 buys. As is a claim that Brainstorm bringing in an amazing board member, but being "ok" with our board with little experience. Who cares about our board right. Unbelievable truly. But oh so expected.
Wonder if any of the 3 firms hired for the ATM, are using the so called "dark pools" to hide sales by our wonderful company. Our how about our newly registered shares for the company lottery coming up in June. Wonder who will win this year, and will most of the approximately 6% dilution event be share giveaways or options, considering they wrote over the word options for the much preferred RSU term.
Remember, no news is good news right. LMBO.
Funny I would have thought it much better to be buying in the $1.30's where we've been for quite some time now, with no upward movement on the horizon. I wouldn't be so happy if I bought into the pump last October, ABOVE and right below that $2 mark. Posts don't lie. Some might call it wise, but I sure wouldn't. A 30% haircut would not be good in my books. But hey, some just love management no matter what it costs them. Just ignore facts and keep on buying at whatever cost. Sound strategy.
LMBOx200,00-195,00. Even closer to reality I'm sure.
Maybe it's because of the more logical reason that there just aren't any valid answers. Hence the silence always.
I guess if Mark Germain stayed with Brainstorm, he would be nowhere close to holding almost 600,000 shares like he is at Pluristem. Brainstorm is much more frugal with what directors receive in stock than we are. They seem to mostly receive options from what I looked at. We like to play by the old adage, you scratch my back, I'll scratch yours. And besides, which board has more experience anyways.
And the CEO was paid $282,500 and received approximately 370,000 options. Not shares. But I guess we are so far ahead of them they all deserve everything they get. Remember, it's biotech!!!
https://finance.yahoo.com/quote/BCLI/holders?p=BCLI
https://finance.yahoo.com/quote/PSTI/insider-roster?p=PSTI
And that leads us around to my question from a different post as to why we have Mark Germain on our board and they don't. Why or how did he leave there at such an early stage of development. Kind of makes you go hmmmm no?
Oops my bad. Mark Germain was and I quote from the bottom of his resume "co founder and director of a number of private companies in the biotechnology field". So impressive we don't even get to hear the names. And I wonder where these companies are now.
And Dr. Moria Kwiat is a Research Fellow in the Department of Material and NanoScience, Faculty of Chemistry at Tel Aviv University
Other than that, zero. I guess due to their extensive background and knowledge of the industry, when they were handing out the bonuses they used the same excuse as many posters here do. Who cares? It's biotech!!!
Since we are doing a little comparison and we have heard some nursery rhyme quotes of late. We can play "one of these things is not like the other". Let's compare their board members and go take a look at Pluristem's and see which one has more pharma experience, and which one has pretty much none, except for one who was a board member at Brainstorm from 2003 to 2004.
Dr. Irit Arbel
Dr. Irit Arbel, one of Brainstorm’s co-founders, joined the Company in May 2004 as a director and served as President of the Company for six months.
Currently, Dr. Arbel is the Chair of the Governance, Nominating and Compensation Committee. Dr. Arbel serves as Executive Vice President, Research and Development at Savicell Diagnostic Ltd. since July 2012. Savicell Diagnostic Ltd. is a biotechnology company and is a wholly-owned subsidiary of Online Disruptive Technologies, Inc. From 2009 through 2011, Dr. Arbel served as Chairperson of Real Aesthetics Ltd., a company specializing in cellulite ultrasound treatment, and BRH Medical, developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early stage technology related companies. Previously, Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems, a biotechnology company, and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company.
Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology, after performing research in the area of Multiple Sclerosis. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel’s Institute of Technology.
Dr. June Almenoff
Dr. June Almenoff is an accomplished executive with 20 years of experience in the pharmaceutical industry. She recently served as President and CMO of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for $1.2B. Furiex developed eluxadoline (VIBERZI®), which was recently approved in both the US and EU. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice-President in the Clinical Safety organization, chaired a PhRMA-FDA working group and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators.
Dr. Almenoff is currently an independent biopharma consultant and Board Director. She is Executive Chair of RDD Pharma and a Director of Tigenix NV (TIG), and Ohr Pharmaceutical (OHRP). She serves on the advisory boards of several private companies and the investment advisory board of the Harrington Discovery Institute.
Dr. Almenoff graduated from the M.D. Ph.D. program at the Icahn School of Medicine at Mount Sinai. She completed her medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine
Arturo Araya
Arturo Araya joined the Company in February 2017 as a director.
Arturo Araya has nearly two decades of international commercial experience in pharmaceutical commercialization, marketing and general management. He was formerly the Vice President and Head of Global Commercial for Novartis’ Cell and Gene Therapies Unit, where he led a cross-functional team to commercialize a portfolio of cell and gene therapies. As Global Brand Leader for CTL019, a CAR-T therapy, he was responsible for developing early launch plans, including worldwide and multiple indication forecasts and resource modeling. He has led the Oncology Unit for Novartis in seven countries. Prior to his tenure at Novartis, Mr. Araya was with Bristol-Myers Squibb Company, most recently as Associate Director of Marketing Intelligence, Business Development & Licensing.
Mr. Araya earned an M.B.A. from the University of Michigan and an M.A. and B.S. in Civil Engineering from the University of Connecticut.
Chen Schor
Chen Schor joined the Company as a director on August 22, 2011, and was appointed as a member of the Audit Committee as of November 9, 2017.
Mr. Schor is a global industry leader with vast experience in biotechnology, medical devices, business development and private equity. Mr. Schor led multiple licensing and M&A transactions valued at over $8 billion with companies such as GlaxoSmithKline, Amgen, Pfizer, Bayer, Merck-Serono and OncoGeneX Pharmaceuticals, and raised significant funds from reputable investors. Mr. Schor has a broad range of experience in multiple therapeutic areas including Neurology, Respiratory, Oncology, Auto-Immune, Genetic Diseases, and Women’s Health. In addition to leading the global business development at Teva Pharmaceuticals, Mr. Schor played a key role in building early stage companies to regulatory approvals, IPOs and M&As. Since December 2014, Mr. Schor has served as Executive Vice President and Chief Operating Officer of Synta Pharmaceuticals Corp., a NASDAQ listed biopharmaceutical company. From March 2009 until September 2011, Mr. Schor served as Vice President of Business Development, global branded products at Teva Pharmaceuticals. Prior to joining Teva, Mr. Schor was Chief Business Officer at Epix Pharmaceuticals, Inc. (formerly known as Predix Pharmaceuticals, Inc.) from December 2003 until March 2009, leading the formation of more than $1.5 billion in collaborations with GlaxoSmithKline, Amgen and additional pharmaceutical companies. Prior to joining Epix, Mr. Schor was a Partner at Yozma Venture Capital from September 1998 until December 2003, managing the fund’s investments in biotechnology and medical device companies.
Mr. Schor previously held positions at Arthur Anderson and BDO Consulting, an advisory firm. Mr. Schor holds an M.B.A., a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant.
Dr. Robert Shorr
Dr. Robert Shorr joined the Company in March 2005 as a director.
Since 1999, Dr. Shorr has served as Chief Executive Officer and Chief Science Officer of Cornerstone Pharmaceuticals, a biotechnology company. He has also been a member of the Department of Biomedical Engineering at SUNY Stony Brook, where he also serves as Director of Business Development for the University’s Center for Advanced Technology. He has served as trustee at the Tissue Engineering Charities, Imperial College, London. From 1999 until 2005, Dr. Shorr was Vice-President of Science and Technology (CSO) of United Therapeutics, a NASDAQ listed biotechnology company. Prior to 1998, he was Vice President, Research and Development at Enzon, Inc., a NASDAQ listed pharmaceuticals company, and AT Biochem, a pharmaceuticals company, of which he was also founder. Dr. Shorr also served on the Board of Directors of Biological Delivery Systems Inc., a NASDAQ listed company.
Dr. Shorr holds both a Ph.D. and a D.I.C. from the University of London, Imperial College of Science and Technology as well as a B.Sc. from SUNY Buffalo.
Malcolm Taub
Malcom Taub joined the Company in March 2009 as a director, and was appointed Chair of the Audit Committee of the Board as of November 9, 2017.
Since October 2010, Mr. Taub has been a Partner at Davidoff Malito & Hutcher LLP, a full service law and government relations firm. From 2001 to September 30, 2010, Mr. Taub was the Managing Member of Malcolm S. Taub LLP, a law firm which practiced in the areas of commercial litigation, among other practice areas. Mr. Taub also works on art transactions, in the capacity as an attorney and a consultant. Mr. Taub has also served as a principal of a firm which provides consulting services to private companies going public in the United States. Mr. Taub has acted as a consultant to the New York Stock Exchange in its Market Surveillance Department. Mr. Taub acts as a Trustee of The Gateway Schools of New York and The Devereux Glenholme School in Washington, Connecticut. Mr. Taub has served as an adjunct professor at Long Island University, Manhattan Marymount College and New York University Real Estate Institute.
Mr. Taub holds a B.A. from Brooklyn College and a 77 J.D. from Brooklyn Law School. Mr. Taub formerly served on the Board of Directors of Safer Shot, Inc. (formerly known as Monumental Marketing Inc.).
Uri Yablonka
EVP, CHIEF BUSINESS OFFICER
Uri Yablonka joined the company on June 6, 2014 as Chief Operating Officer and as a member of the Board of Directors.
Prior to joining the Company, Mr. Yablonka served since December 2010 as owner and General Manager of Uri Yablonka Ltd., a business consulting firm. He also served since January 2011 as Vice President, Business Development at ACC International Holdings Ltd. (Holdings). Holdings is also an affiliate of ACCBT Corp. Prior to serving with Holdings, Mr. Yablonka served as Senior Partner of PM-PR Media Consulting Ltd. From 2008 to January 2011, Mr. Yablonka was Senior Partner at PM-PR Media Consulting Ltd., where he led public relations and strategy consulting for a wide range of governmental and private organizations.
From 2002 to 2008, he served as a correspondent at the Maariv Daily News Paper, including extensive service as a Diplomatic Correspondent.
Wow people must really want me to compare other companies to us now. One product in phase 3 as well. A third of our market cap. Just a quick look at one thing from Brainstorm's quarterly report. How does this differ from our now 2 ceo's. The following seems just a little more reasonable don't you think. Maybe our stellar board should have used this company when comparing compensation. Instead of NO comparisons.
On July 26, 2017, the Company granted to its Chief Executive Officer 31,185 shares of restricted common stock, which vests as to twenty-five percent (25%) of the award on each of the first, second, third and fourth anniversary of the date of grant, provided grantee remains continuously employed by the Company from the date of grant through each applicable vesting date, and is subject to accelerated vesting upon a Change of Control (as defined in an agreement with grantee) of the Company. In the event of grantee’s termination of employment, any portion of the grant that is not yet vested (after taking into account any accelerated vesting) shall automatically be immediately forfeited to the Company, without the payment of any consideration to grantee.
On July 26, 2017, the Company granted to its Chief Executive Officer an option to purchase up to 41,580 shares of Common Stock at an exercise price per share of $4.81. The option is fully vested and exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant, regardless of whether grantee remains employed by the Company.
Hey Spidey,
I have posed questions directly to you, among others in the past and you remained silent. If this is just the same old circles as you say, why did you break that silence? It was a pretty good comparison of 2 companies that started at similar times, in a similar field, with zero similarities between board and management experience. Must have thought it was a good one for you to respond to no?
I question you to your thoughts of the update, and you just said its 2 weeks old and was already discussed. Did you post anything when it was new enough for you. Now that 2 weeks has passed its irrelevant?
Or how I question the delays for preclinical results, the ones that use mice. No enrolment difficulties, doubtful ethical delays would come into play. Not all missed milestones are cut from the same cloth. But yet, no response.
Or how about other companies abilities to manufacture cells in commercial quantities that was discussed in the last week? That's pretty new don't you think? Allo had been making the claim that nobody can manufacture like we can since as long as I can remember. It was our ace in the hole. Allo tried to refute it with mab's or some other pretty funky terms. Where were my props on this new find? Lol.
.
How come you didn't weigh in on the subject, especially when Allo's throwing terms out that are more up your ally. Even Pluristem took down the info about others growing in Petri dishes from their presentations. I wonder why. But what are you're thoughts on this if its still new enough for you, or Allo's response is considered dealt with already, since nobody else broke their silence on the topic.
Mesoblast even uses the term 3d bioreactor on their website. Should we be concerned with that, or not discuss it. That goes for the 2000L biorectors that companies are using. Not worthy of conversation?
Allo does post a lot of useful links, that I can agree. But how do you remain silent on the added commentary that goes along with them? Why does nobody but a handful of us, question these thoughts. Do you agree with them, as yours and everyone's silence on the many subjects would tend to make one believe that people are in agreement with these highly improbably thoughts.
And we all know the clueless and sideline Sally and such, they throw out there. My skin is thick enough to respond to them, as I know most of the commentary section in his posts are made up. You want to praise him for his posts, yet base a decision not to respond to me because of what I say. Kind of double standard don't you think.
I. would like to talk about Israel Ben Yoram. I found a link showing Brainstorm was founded in 2013, so it is feasible that he was a director at that time. I'm sure his role there was crucial to the startup of that company. Wish I could find a reason somewhere as to why he left or they chose someone else. But why is he not still there and on our board.
Seems most of our board has to do with financial experience in startups. You know, doing raises, bringing investors in for when they do them. Why can't we have board members with serious experience in pharmaceutical companies? Maybe then we would be further along in all of our trials, and not masters of dilutions. We have long moved past the start up phase. Time to move along to board members who can assist in another field like partnering for once.
When you say you're "ok" with them, is that not justifying them. What's your take on the update since you haven't chimed in as of yet.
We got a letter to shareholders Spidey. Is that not something "new". Do you somehow agree that we made "most milestones". Laughable truly. This is straight from the leaders mouth, the one you try to defend. How can you defend that? Have you ever once responded to that!
Yes clearly YOU should stop with your attempts to justify our management. Argument is definitely lacking to say the least. And hence your desire to see others stop arguing that agree with me, with a substantial amount of pretty solid reasons. At least it's pretty obvious why these points are always overlooked. At least you tried this time.
Sorry Spidey many intangibles to shareholder value. Stock price isn't the only one unfortunately. Waiting for multiple phase 3 results is one of them. Hit on one of them and see what happens to share price. Unfortunately we just started our first. And most likely will be a couple of years before anything is known. Especially since the epic fail of their goal to have 40 sites online by eoy 17. But let me guess, the number of sites doesn't matter.
I know Eichking it is plain as day for everyone to see. Just like to counter the attempts to discredit my claims with pretty much little to no argument. Always avoid management discussions like the plague. Unfortunately there's not much ammo to counter, try or not try as they may. Maybe some should stick to their areas of "expertise". How a company is run is obviously not a strength for any of them.
If you saw it, why not mention it then since you are basing your argument on the financial stats? Yes they have not driven up value yet. But they most certainly have a "coiled spring" that one claims we have. They are progressing in their plan quite well don't you think? I don't claim to know their plan as I don't. But on the outside looking in, 9 phase 3's would seem to substantiate that don't you think. And with 35 trials on Clinicaltrials site, do you think they made jumps from phase 1 to 3 like we are. Cuts down on costs yes, but increases risk accordingly. We will see what happens on our one and only phase 2 to be announced soon. How do these facts compare with ours?
You can stop trying to go on about management with yours and others claim to be "ok" with it. Truly don't think anyone here with an ounce of objectivity agrees. I certainly do not. And I most certainly will not stop bringing this huge side of the equation up, as it's just as important, if not more, than the technology we claim to have.
Sorry Spidey you most certainly did. Just like Zzatt and Happy did
You're comparison for stock price is weak as well. They too are a developing company just like we are. Just light years ahead on their plan. Like you and others say, there's more to a stock than price right. Or is that argument only fitting when it comes to our stock.
They have revenue now, unlike us. That revenue will most likely increase, as products come on line. What will happen to their price if their phase 3 trials they're awaiting results on are good. At least that have completed phase 3's. We have completed zero, and have one phase 2 awaiting results. How does that compare to what they have accomplished? what did they just announce phase 3 results from? GvHD. We will be starting a phase one in that soon. Ahhhh but we can manufacture cheaper. That's all that matters. Did you see their market cap? Over half a billion? Their stock moves when they accomplish things. Ours sits still as if nobody cares. Or maybe because they accomplish things at a snails pace. All comes round and round in circles like you say for one reason. I'll let you avoid that answer yet again.
Another great argument. Thanks Happy. Eerily similar to two others today. At least you didn't cut and paste like someone else today. Or edit them.
Thanks EichKing. Couldn't say it any clearer yet again. Really I could care less about the people who avoid any factual information about management. They are a tight knit group who always have the same statements or lack thereof.
Hopefully something has sunk in with others who are part of that "group". We have shown time and time again, and that's all we can do. This stock is a gamble at best, and should be treated as such. I too believed strongly in this company, but have lost pretty much all faith in their ability to execute. Again, the best technology in the world is irrelevant, without the proper people in place to make it happen. Mesoblast is succeeding, we are moving at a snails pace at best. Not the scientists or technologies fault. That rests one one, now 2 people's heads.
Hey Spidey,
If someone want to attempts to respond to my claims, should I just stay silent? Doesn't know but probably better funded was the argument wasn't it? My response backed up my argument that management is responsible for that side. Are all the top notch scientists responsible for that? No, management is. Did you read my post. 9 phase 3's. How are they executing their plan with precision. How are we failing so obviously compared to them.
The proverbial I'm "ok" with them is alarming to say the least. Just like you're "ok" with them. Just ignore how a comparative company who started 3 years after us, is so farther ahead because I might respond to them. Great argument not to respond. Seems to be the norm don't you think?
Just like your argument of CLI interim results. Just divide the timeline posted on clinicaltrials site in half, and that's the possibility. No comment on site enrolment miss by having 14 active sites instead of the goal of 40 by year end like they put out a news release on. Or is that the top notch scientists fault.
Just dismiss my posts because of how I come across. Wow. That's impressive. I'm sure Gary has endured more in his life and can take a little critique form another poster, and doesn't need you to run to his defence. But kudos for him to at least try, unlike you.
See Gary, that is a pretty weak argument. You mention Meso was probably better financed. Really? Look at what they have accomplished. Of course they were. Why or how? Management. Plain and simple. You use the I'm "ok" with them. It astonishes me how you can be. Sick of people saying this truly and draws suspicion to say the least. If you actually own shares, why are you ok with it.
You could have the best scientists in the world, but if you have horrible management, good luck. Do you think management and board members with huge connections have anything to do with their ability to partner or raise funds without diluting the crap our if a company. To have a vision and stick with it, not changing direction every couple of years.
I could care less if they are using pig stem cells. Not my point in the least. It was a comparison of sorts between 2 companies and where they stand today. Just look at the number of trials. Truly remarkable. They have accomplished so much more with 3 years less time.
It's amazing what great management can get done. How to maximize the value of their employees. We send them to shows.
And Gary, I understand these things take time. Management should be straight up and put attainable goals out there. Would be more prudent don't you think. Unfortunately I truly don't think they have any clue themselves. Just put out what they think shareholders want to hear.
Part of my whole point to that post was to show Allo that his thought that we could get approval for CLI in late 2018 is absurd to say the least. Will NEVER happen.
It's funny how the FIRST paragraph of their letters to shareholders had to do with milestones. I truly think they are starting to feel the heat. Rightfully so. Truly hope Zami has some scruples and steps down before he blows this company up or takes it to a point of no return.
After looking at Mesoblast, even if we got funding of $50 million for ARS, don't think it will take us much over $2 if at all. If it does, don't think it will stay there.
Too many people here call this management bashing. I call it the truth. I anxiously await to here you, Zzatt, Spidey, MC, the saud, Melon, n3, JP, Dog, anyone try to give reasons why they believe this management team is capable of what we need after looking at the comparison to Mesoblast. Sadly I anticipate silence like always whenever I bring up valid facts with regards to our management and board.
Management is CRUTiAL in any company. Why or how people think otherwise is astonishing truly. Only people with different agendas here than I, could still think management and board is irrelevant.
I truly hate when I look into other companies. It makes me wonder where we would be if we had seasoned veterans running this company. I honestly think we would be farther ahead of Mesoblast, instead of being miles behind. But hey what do I know. I'm just a management basher.
And have a look at their section on manufacturing below. They seem to be advancing towards 3d manufacturing. And also notice who does their manufacturing other than the procurement and creation of master cell banks....Lonza. They need what we have though. Wow even other companies utilizing 3d bioreactors. Are they scared or out patents or are they doing something that will circumvent the patents. Ses to me our parents aren't as big a deal as some claim they are.
"We have developed manufacturing processes employing two dimensional (2D) technology, and have made significant advances in the development of three dimensional (3D) bioreactor technology. Our manufacturing activities have met stringent criteria set by international regulatory agencies.
Our MLC–based product manufacturing and distribution process generally involves five major steps:
Acquire bone marrow from healthy adults with specific regulatory defined criteria, which is accompanied by significant laboratory testing to establish the usability of the donated tissues.
Create master cell banks by isolating MLCs from the donated bone marrow and performing a preliminary expansion to create master cell banks. Each individual master cell bank comes from a single donor.
Expand to therapeutic quantities by growing cells in the master banks to produce therapeutic quantities. This process that can yield thousands of doses per master cell bank, with the ultimate number depending on the dose for the respective product candidate being produced.
Formulate, package and cryopreserve
Distribution With the exception of procurement and creation of master cell banks, our manufacturing is conducted by Lonza in its Singapore facility then shipped to distribution or treatment centers."
So tell me Gary how does Mesoblast do what I stated in my last post.
Yes Mesoblast. Rah rah rah. Great for the space. Celularity is just a joke. But let's cheer Mesoblast. Lets look into them a little.
Founded in 2004. We were founded in 2001.
35 trials on Clinicaltrials. We have 6.
9 phase 3 trials. 2 completed, 3 recruiting, 4 awaiting results. We have 1 that just started.
How can this be? We started 3 years before them. We have the best product though right? After taking a look at Meso, I'm surprised we have the market cap we have. It ALL comes down to management, board, experience, CONNECTIONS, industry know how, the direction chosen, etc. All decided by management. What else can it be??? To deny this fact is a joke. I guess it is the controller right. Is that what you are going to believe??? I am open to other thoughts. Like usual, I will only expect one to twist it somehow, and another to congratulate.
Please go take a look at their management team. See the difference for yourselves. Just look at the overview of their management team. Then look at the big Pharma names most came from.
Mesoblast has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and biotechnology companies. This team is responsible for the strategic direction, operations and success of our company.
Here's the link. Wipe the spit off your chin after.
http://mesoblast.com/company/management-team
And some snippets from the board. Again get some Kleenex handy for the chin.
Brian Jamieson, FCA
Chairman since 2007 after retiring as Chief Executive of Minter Ellison Melbourne. Previously he was CEO at KPMG Australia,
William M. Burns, BA
Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 200@
Donal O’Dwyer, BE, MBA
he worked with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences.
Ben-Zion Weiner, BSc, MSc, PhD
Dr Weiner has served on our Board of Directors since 2012. In a 37-year career at Teva Pharmaceutical Industries Ltd, he held various senior research and development positions, including Senior Vice President of Global Research and Development.
You're right!!! I forgot about the 2 Israeli sites. You prove your points well. Kudos. CLI will be finished this year for sure. They do make "most of their milestones" right. And even more earlier than expected.
We are approaching 13 months since enrolment began in HCT trial. They hired a secretive "leading" CRO remember. Maybe it was so they can keep their definition of "leading" a secret. They think Pluristem are "leaders" after all. And resumes are chalked full of terms like "successful companies" without giving the actual names of them. Keeps em guessing. So it MUST be incredible.
Four sites trying to recruit 30 patients. Less than 8 per site. If they get one per month per site, we will be done by.... Um...last year. But I guess this is not a serious condition like CLI so enrolment would be slow.
But CLI boy, we're going to get approved this year for sure!!! They only need 123 enrolled. 14 sites probably easily enrolling patients. Piece of cake. Probably just going to halt the trial outright, and approve immediately. Did anyone in the two trials of 27 patients not make it to 1 year AFS? And statistical trials aren't really necessary. More of a way to just keep FDA workers employed. If it works on one, good for all.
I can't believe this phase 3 company is sitting in the $1.30's. Must be the controller. It's the only explanation. Remember everyone should load up... anything under $2 is a steal. Besides, once that deal is signed, the controller will go away. Whew!!!
You can say that again. I found this example for the simple minds, simple pleasure quote I did. Pretty fitting don't you think. And I'm with you on humour. Unfortunately with the state of Pluristem and management, hard to find the humour.
"For example, I'd say "Simple minds, simple pleasures" likely originated in a breakroom in corporate America where employees were ooohing and ahhhing over a new vending machine."
Please show me where you discussed the first paragraph? And of course you would. Or are you confused with someone else.
LMBOx200,000. You know why.
And there it is like clockwork. I guess you like the first paragraph of the letter to shareholders too? There's an old saying...Simple minds, simple pleasures.
Funny the lack of originality in posts. Just the same things over and over again. We post real posts with facts. New things that come about ANY time Pluristem comes out with anything.
Unfortunately, as you know, it's not too often. But when it comes, it's full of gaffs and errors which these twins are best at.
We all know you belieb, don't worry. We all know you belieb management is great, no matter how many posts show their lack of credibility and ineptitude. We know you belieb competition doesn't matter. We know you belieb manufacturing advantage was lost, but that doesn't matter. We know that you belieb if you just keep beliebing, everything will just fall into place in the next decade. Belieb all you want, facts are facts.
Maybe we should have a new "chosen one" for obvious reasons.
LMBOX200,000-195,000
Should be getting the cheers from the other "original" ones any moment.
No just no details to provide as there are none. Try the following lines. Just pretend and now keep those milestones at 12 months on every presentation from now on.
"This year most milestones were met"
Or
"But we were pleasantly surprised to achieve other, unexpected milestones"
Yes those hidden milestones. Or maybe they live in Bizzaro world where failed equals made. No way to justify those lines whatsoever. Again, providing factual evidence, is not defamatory.
But what you and other coworker's post here has a different term to it.
If you read the this first paragraph of the letter to shareholders, you will realize that chance is slim with the incompetent ones steering this ship. Anyone care to stand up and try and justify this joke of a paragraph. Pretty hard challenge I agree.
"Pluristem had a very busy 2017, filled with significant achievements. Our management team has been working hard to ensure that we reach our milestones. This year, most milestones were met, others unfortunately were not, but we were pleasantly surprised to achieve other, unexpected milestones throughout the year as well. While we can’t address all the details, we are hopeful that this letter will provide valuable updates and insight, on some of our programs."
Want a real laugh look no further than the first paragraph of the letter to shareholders. Nothing to date shows just how credible the quackies are. Zip zero zilch. Straight from the horses mouth, and another perfect example as to why they don't do CC's or anything but shows where they're hoping most are deep into the booze and don't realize how inept they truly are. Next they will try to rufi someone and get their signature on a partnership. Desperate times calls for desperate measures. This IS half of our fearless leader. I'd be more concerned with this Zzatt than how people write on this board. Talk about gibberish. LMBO
"Pluristem had a very busy 2017, filled with significant achievements. Our management team has been working hard to ensure that we reach our milestones. This year, most milestones were met, others unfortunately were not, but we were pleasantly surprised to achieve other, unexpected milestones throughout the year as well. While we can’t address all the details, we are hopeful that this letter will provide valuable updates and insight, on some of our programs."
How did they write that with a straight face. They must have been huddled together laughing thinking can you believe some shareholders might actually believe this. Ask yourself this...do you.
We have 2 now that BELIEB in the strong retail hands. Validation now.
And here I thiught I heard it all. That should make the greatest hits list. Institutions can't get them because of the strong hands of retail. You did not just say that.
LMBOx200,000. You know why.